Poland· PL-100511935
Hympavzi
A other systemic hemostatics product containing marstacimabum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Marstacimabum is registered in 3 of 19 countries.
Countries holding a registration under ATC B02BX (other systemic hemostatics), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Marstacimabum · ATC B02BX
3 / 19 countries
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Marstacimabum
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Poland (PL)
- ATC code
- B02BX
- ATC class
- Other systemic hemostatics
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Marstacimabum in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandHympavzi
- United StatesHYMPAVZIPfizer Laboratories Div Pfizer Inc
- IrelandHympavzi 150 mg solution for injection in pre-filled penPfizer Europe MA EEIG
- CzechiaHYMPAVZIPfizer Europe MA EEIG, Bruxelles
- IcelandHympavziPfizer Europe MA EEIG*
- FinlandHympavziPfizer Europe MA EEIG
- BelgiumHympavzi 150 mgPfizer Europe MA
- NetherlandsHympavzi 150 mg oplossing voor injectie in een voorgevulde penPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Hympavzi
- Liechtenstein · Hympavzi
- Norway · Hympavzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/954fa26f-5561-4ef7-82aa-3d84c9679098 GET /v1/drugs/954fa26f-5561-4ef7-82aa-3d84c9679098?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "150 mg/ml",
"packaging": "Rpz ¦ EU/1/24/1874/001 ¦ 159946\n1 amp.-strzyk. 1 ml",
"substance": "Marstacimabum 150 mg/ml",
"common_name": "Marstacimabum",
"pl_product_id": "100511935",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about marstacimabum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.